MedTrace Logo

Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution

NCT02325518 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 218

Last updated 2016-12-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate AZORGA® Ophthalmic Suspension compared to COSOPT® Ophthalmic Solution for IOP-lowering efficacy in subjects with open-angle glaucoma or ocular hypertension.

Conditions

Interventions

DRUG

Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension

DRUG

Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution

DRUG

Subject's habitual PGA monotherapy

Sponsors & Collaborators

  • Alcon, a Novartis Company

    lead INDUSTRY

Principal Investigators

  • Clinical and Regulatory Affairs · Alcon Japan, Ltd.

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02325518 on ClinicalTrials.gov